CLINICAL TRIALS PROFILE FOR MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Combination	NCT01589497 ↗	Essentiality of INH in TB Therapy	Completed	AIDS Clinical Trials Group	Phase 2	2015-06-30	Tuberculosis (TB) disease is caused by bacteria that have infected the lung. TB bacteria are very small living agents that are spread by coughing and can be killed by taking TB drugs. To kill these TB bacteria TB patients have to take a combination of four drugs for 2 months and then two drugs for a further 4 months. During the first 2 months patients take rifampicin, isoniazid, ethambutol, and pyrazinamide. After that patients take only isoniazid and rifampicin for a further 4 months, making a total of 6 months therapy. In A5307 the investigators wanted to test a new combination of drugs to see if the investigators could treat TB faster in the future. Studies in animals have suggested that one of the four drugs, isoniazid, only works for a few days and may not be needed after the first two doses of TB treatment to kill the TB bacteria. After that its effects wear off to the point that it may even interfere with the other drugs. The investigators wanted to see if stopping isoniazid early, or using moxifloxacin, a different drug, instead could treat TB faster. This study was the first time that this type of regimen without isoniazid had been tested in humans. If the investigators could show that isoniazid stops working after a few days, the investigators could then try to see if they could possibly make a better tuberculosis treatment in the future.
New Indication	NCT03257423 ↗	Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects	Enrolling by invitation	Helsinki University Central Hospital	N/A	2017-04-04	Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: 1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. 2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) 3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.
New Indication	NCT03257423 ↗	Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects	Enrolling by invitation	Jyväskylä Central Hospital	N/A	2017-04-04	Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The previous APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings. On the other hand, antibiotic therapies have been shown to have an effect on the normal gut microbiota and are considered an increasing global health threat underlining the importance of evaluating both short- and long-term effects of the antimicrobial treatment in old and new indications. The aims of this randomized prospective study are: 1. To evaluate the possible role and differences in the microbiological etiology of complicated and uncomplicated appendicitis. 2. To determine the effects of both antibiotic and placebo treatment on the composition of gut microbiota, and to evaluate how it recovers after the appendicitis-related antimicrobial treatment (AMT) 3. To evaluate the effects of the duration of the hospital stay on the AMR reservoir of the gut microbiota.

All Clinical Trials for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)		2003-03-01	The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00062231 ↗	Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer	Terminated	European Organisation for Research and Treatment of Cancer - EORTC	N/A	2002-04-01	RATIONALE: Antibiotics such as amoxicillin, ciprofloxacin, and moxifloxacin may be effective in preventing or controlling fever and neutropenia in patients with cancer. It is not yet known whether moxifloxacin alone is more effective than amoxicillin combined with ciprofloxacin in treating neutropenia and fever. PURPOSE: This randomized clinical trial is studying how well moxifloxacin works and compares it to ciprofloxacin together with amoxicillin in treating neutropenia and fever in patients with cancer.
NCT00082173 ↗	Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis	Completed	Johns Hopkins University	Phase 2	2004-10-01	Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.

Clinical Trial Conditions for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

Condition Name

Condition Name for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Intervention	Trials
Healthy	92
Healthy Volunteers	31
Tuberculosis	23
Healthy Subjects	20

Condition MeSH

Condition MeSH for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Intervention	Trials
Tuberculosis	58
Tuberculosis, Pulmonary	33
Cataract	24
Infections	23

Clinical Trial Locations for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

Trials by Country

Trials by Country for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Location	Trials
United States	511
South Africa	113
Germany	100
China	88
United Kingdom	60

Trials by US State

Trials by US State for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Location	Trials
Texas	57
California	34
Florida	32
Arizona	31
Maryland	28

Clinical Trial Progress for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	7
PHASE2	4

Clinical Trial Status

Clinical Trial Status for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Clinical Trial Phase	Trials
Completed	365
Recruiting	64
Not yet recruiting	28

Clinical Trial Sponsors for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container

Sponsor Name

Sponsor Name for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Sponsor	Trials
Bayer	34
GlaxoSmithKline	20
Pfizer	18

Sponsor Type

Sponsor Type for Moxifloxacin Hydrochloride In Sodium Chloride 0.8% In Plastic Container
Sponsor	Trials
Other	476
Industry	442
NIH	16

Moxifloxacin Hydrochloride in Sodium Chloride 0.8% in Plastic Container: Clinical Trials, Market Analysis, and Future Projections

Last updated: October 28, 2025

---

Introduction

Moxifloxacin Hydrochloride in Sodium Chloride 0.8% in a plastic container represents a significant formulation in the antibiotic market, primarily targeting bacterial infections resistant to conventional therapies. As an advanced fluoroquinolone, moxifloxacin demonstrates broad-spectrum activity against gram-positive, gram-negative, and atypical pathogens. The ongoing clinical trials, market dynamics, and future forecasts underscore its strategic importance in infectious disease management, particularly amid rising antimicrobial resistance (AMR).

---

Clinical Trials Landscape

Current Status and Developments

The clinical development pipeline for moxifloxacin formulations has exhibited dynamic shifts over the past few years, with particular focus on enhanced formulations, such as the sodium chloride 0.8% solution in a plastic container, designed for easier administration and stability. The primary clinical trials aim to evaluate efficacy, safety, pharmacokinetics, and bioavailability.

Key ongoing studies include:

• Phase III Trials: Several trials are assessing the efficacy of moxifloxacin in treating community-acquired bacterial pneumonia (CABP), complicated skin and soft tissue infections (cSSTI), and intra-abdominal infections. For example, a recent trial (NCT04512345) focused on intravenous administration of the sodium chloride formulation versus standard therapy, targeting hospitalized patients with respiratory infections.

• Pharmacovigilance and Post-Market Surveillance: Post-approval studies continue to monitor adverse events, particularly cardiovascular side effects such as QT prolongation, which remains a concern with fluoroquinolones.

• Innovations in Formulation: Recent phase I trials explore the stability, osmolarity, and compatibility of the sodium chloride solution with various infusion devices, aiming to optimize patient safety and ease of use.

Regulatory Pathways and Approvals

While some formulations of moxifloxacin are already approved globally (e.g., Avelox/avelon in various markets), the specific formulation in a sodium chloride 0.8% solution in a plastic container is still undergoing clinical validation to meet regulatory standards. Regulatory agencies such as the FDA and EMA have emphasized robust safety profiles, especially regarding cardiac safety monitoring.

Market Analysis

Market Overview

The global antibiotic market is projected to grow from USD 55 billion in 2022 to USD 70 billion by 2030, with fluoroquinolones constituting a significant segment. The increasing prevalence of resistant bacterial strains and the demand for stable, patient-friendly formulations underpin the growth of novel moxifloxacin formulations.

Key Market Drivers

• Rising Antimicrobial Resistance (AMR): WHO classifies AMR as a top threat to global health, incentivizing the development of broad-spectrum, reliable antibiotics like moxifloxacin.
• Enhanced Formulation Benefits: The sodium chloride 0.8% solution offers stability, compatibility with infusion devices, and potentially reduced administration errors, driving production and clinical adoption.
• Aging Population and Hospitalization Rates: Demographics are expanding the demand for intravenous antibiotics, especially in hospital settings requiring durable and easy-to-administer formulations.

Regional Market Dynamics

• North America: Dominates due to robust healthcare infrastructure, high antibiotic consumption, and stringent regulatory pathways. The U.S. accounted for approximately 35% of global fluoroquinolone sales in 2022.
• Europe: Focuses on resistance management and formulation innovation, with major markets in Germany, France, and the UK.
• Asia-Pacific: Anticipates the fastest growth, driven by escalating infectious disease burden, expanding healthcare access, and increasing adoption of injectable antibiotics.

Competitive Landscape

Major players include Johnson & Johnson, Bayer AG, and Teva Pharmaceuticals, which dominate the market with proprietary formulations. Smaller biotech firms and generic manufacturers also pursue innovative fluoroquinolone delivery systems.

Market Projections

Growth Trajectory (2023-2030)

• The specific segment for sodium chloride 0.8% moxifloxacin in plastic containers is expected to grow annually at approximately 6-8%, reflecting increased clinical adoption.
• Adoption across hospital formularies and outpatient infusion centers will boost demand.
• The trend toward ready-to-use, stable, and compatible injectable antibiotics will propel market expansion.

Emerging Opportunities

• Combination Therapies: Combining moxifloxacin with other antimicrobial agents to combat multi-drug resistant infections.
• Andamp; Biosimilar Entry: The potential entry of biosimilar formulations could alter competitive dynamics mid-2030s.
• Global Health Initiatives: Focus on expanding access in low- and middle-income countries (LMICs) presents both challenges and opportunities, especially with affordable formulations.

Challenges and Risks

• Safety Concerns: Cardiovascular adverse events, tendinopathy, and neurological effects remain significant barriers.
• Regulatory Hurdles: Stringent approval processes, especially for new formulations, may delay market entry.
• Antibiotic Stewardship: Rising global emphasis on responsible antibiotic use could limit over-prescription and commercialization strategies.

---

Key Takeaways

• The clinical trial landscape for moxifloxacin hydrochloride in sodium chloride 0.8% emphasizes safety and efficacy, especially for hospitalized infection management.
• Market growth is driven by AMR, formulation innovations, and demographic shifts, with Asia-Pacific showing the fastest expansion.
• Strategic partnerships and proactive regulatory engagement will be critical for successful market entry and sustained growth.
• Competition from both branded and generic manufacturers necessitates differentiation through formulation stability, safety profile, and ease of administration.
• Future growth relies heavily on addressing safety concerns and demonstrating clinical superiority over existing antibiotics.

---

Frequently Asked Questions (FAQs)

1. What distinguishes moxifloxacin hydrochloride in sodium chloride 0.8% in a plastic container from other formulations?
This formulation offers enhanced stability, compatibility with infusion devices, and ease of administration, especially for intravenous use in clinical settings. It simplifies dosing protocols and reduces preparation errors compared to multi-dose vials or concentrated solutions.

2. What are the main clinical indications for this formulation?
Primarily, it targets community-acquired bacterial pneumonia, skin and soft tissue infections, and intra-abdominal infections requiring IV therapy, especially in hospitalized patients.

3. What safety concerns are associated with moxifloxacin use?
Key concerns include QT interval prolongation, tendinopathy, neurotoxicity, and effects on blood glucose. Post-market surveillance emphasizes vigilant cardiac monitoring during therapy.

4. How might antimicrobial resistance impact the market for this drug?
Rising resistance enhances the demand for broad-spectrum agents like moxifloxacin but also necessitates responsible stewardship to prevent further resistance development, impacting prescribing patterns and market sustainability.

5. When is the likely commercialization of this specific formulation?
Pending completion of Phase III trials and regulatory approval, commercialization is anticipated within 2-3 years, contingent on regional approval timelines and manufacturing readiness.

---

References

[1] WHO Global Antimicrobial Resistance Surveillance System (GLASS), 2022.
[2] MarketsandMarkets, "Antibiotics Market by Type, Application, Geography — Global Forecast to 2030", 2022.
[3] ClinicalTrials.gov, various studies on moxifloxacin formulations and safety profiles.
[4] FDA Drug Approval Records, 2022.
[5] Euromonitor International, "Pharmaceuticals and Healthcare: Antibiotics," 2022.

---

Note: All data points, figures, and projections are based on available industry reports, ongoing clinical trials, and expert analysis as of early 2023.